[go: up one dir, main page]

NO20054868L - CaSr antagonist - Google Patents

CaSr antagonist

Info

Publication number
NO20054868L
NO20054868L NO20054868A NO20054868A NO20054868L NO 20054868 L NO20054868 L NO 20054868L NO 20054868 A NO20054868 A NO 20054868A NO 20054868 A NO20054868 A NO 20054868A NO 20054868 L NO20054868 L NO 20054868L
Authority
NO
Norway
Prior art keywords
compound
calcium
casr antagonist
antagonist
osteoporosis
Prior art date
Application number
NO20054868A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054868D0 (no
Inventor
Yuko Shinagawa
Teruhiko Inoue
Toshihiro Kiguchi
Taku Ikenogami
Naoki Ogawa
Kenji Fukuda
Takashi Nakagawa
Masanori Shindo
Yuki Soejima
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of NO20054868D0 publication Critical patent/NO20054868D0/no
Publication of NO20054868L publication Critical patent/NO20054868L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/80Acids; Esters in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
NO20054868A 2003-04-23 2005-10-21 CaSr antagonist NO20054868L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003119131 2003-04-23
PCT/JP2004/005886 WO2004094362A1 (fr) 2003-04-23 2004-04-23 Antagoniste de casr

Publications (2)

Publication Number Publication Date
NO20054868D0 NO20054868D0 (no) 2005-10-21
NO20054868L true NO20054868L (no) 2005-12-20

Family

ID=33308093

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054868A NO20054868L (no) 2003-04-23 2005-10-21 CaSr antagonist

Country Status (30)

Country Link
US (4) US7304174B2 (fr)
EP (3) EP1619180B1 (fr)
JP (1) JP3751312B2 (fr)
KR (1) KR100696927B1 (fr)
CN (2) CN100577633C (fr)
AR (1) AR044075A1 (fr)
AT (1) ATE452121T1 (fr)
AU (1) AU2004232604C1 (fr)
BR (1) BRPI0407097A (fr)
CA (1) CA2513738C (fr)
CL (1) CL2004000868A1 (fr)
CO (1) CO5640091A2 (fr)
CY (1) CY1109880T1 (fr)
DE (1) DE602004024668D1 (fr)
DK (1) DK1619180T3 (fr)
ES (1) ES2337576T3 (fr)
HR (1) HRP20100042T1 (fr)
IL (1) IL169575A (fr)
MX (1) MXPA05007609A (fr)
MY (1) MY138734A (fr)
NO (1) NO20054868L (fr)
NZ (1) NZ541188A (fr)
PE (1) PE20050460A1 (fr)
PL (1) PL1619180T3 (fr)
PT (1) PT1619180E (fr)
RU (1) RU2315036C2 (fr)
SI (1) SI1619180T1 (fr)
TW (1) TWI329628B (fr)
WO (1) WO2004094362A1 (fr)
ZA (1) ZA200505587B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
JPWO2004106280A1 (ja) * 2003-05-28 2006-07-20 日本たばこ産業株式会社 CaSRアンタゴニスト
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US20070155819A1 (en) * 2004-02-06 2007-07-05 Marquis Robert W Jr Calcilytic compounds
WO2007124465A2 (fr) * 2006-04-20 2007-11-01 Amgen Inc. Formules d'émulsions stables
WO2008121386A2 (fr) 2007-03-30 2008-10-09 Amgen Inc. Procédés de traitement de troubles intestinaux
US8039514B2 (en) * 2008-06-05 2011-10-18 Asahi Kasei Pharma Corporation Sulfonamide compounds and use thereof
ES2412408T3 (es) * 2008-12-24 2013-07-11 Daiichi Sankyo Company, Limited Compuestos de indanilo
NZ593675A (en) * 2008-12-24 2012-06-29 Daiichi Sankyo Co Ltd Cyclic amine compounds
WO2010104882A1 (fr) 2009-03-10 2010-09-16 Amgen Inc. Procédés de modulation de la motilité des spermatozoïdes
WO2010103429A1 (fr) * 2009-03-10 2010-09-16 Pfizer Inc. Dérivés de l'acide 1,1-(diméthyl-éthylamino)-2-hydroxy-propoxy]-éthyl}-3-méthyl-biphényl-4-carboxylique utiles en tant qu'antagonistes des récepteurs du calcium
CN102365261A (zh) * 2009-03-26 2012-02-29 日本烟草产业株式会社 制备羧酸化合物的方法
WO2010113860A1 (fr) * 2009-03-31 2010-10-07 第一三共株式会社 Composé biphényle-amine cyclique
US8785494B2 (en) 2009-05-27 2014-07-22 Leo-Pharma A/S Calcium sensing receptor modulating compounds and pharmaceutical use thereof
EP2435404A1 (fr) 2009-05-27 2012-04-04 Leo Pharma A/S Nouveaux composés modulant le récepteur sensible au calcium, et leur utilisation pharmaceutique
EP2643292A1 (fr) 2010-11-26 2013-10-02 Leo Pharma A/S Composés actifs sur les récepteurs du calcium
RU2013128950A (ru) * 2010-11-26 2015-01-10 Лео Фарма А/С Замещенные циклопентилазины в качестве casr-активных соединений
WO2012069420A2 (fr) 2010-11-26 2012-05-31 Leo Pharma A/S Composés actifs sur le récepteur sensible au calcium
EP2643290A1 (fr) 2010-11-26 2013-10-02 Leo Pharma A/S Composés actifs sur le récepteur sensible au calcium
GB201113538D0 (en) * 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
WO2014033604A1 (fr) * 2012-08-27 2014-03-06 Lupin Limited Composés d'arylalkylamine jouant le rôle de modulateurs des récepteurs sensibles au calcium
IL263494B2 (en) 2016-06-13 2024-01-01 Syneurx Int Taiwan Corp Use of lithium benzoate for treating central nervous system disorders
AU2020399030A1 (en) * 2019-12-09 2022-06-23 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Calcium-sensing receptor agonist compound and application thereof
KR20230106582A (ko) * 2020-08-04 2023-07-13 캘시리틱스 테라퓨틱스, 인코포레이티드 트리페닐 칼실리틱 화합물의 제형
KR20230112609A (ko) * 2020-09-18 2023-07-27 캘시리틱스 테라퓨틱스, 인코포레이티드 상염색체 우성 저칼슘혈증 타입 1(adh1)의 치료를 위한 트리페닐 칼시라이틱 화합물
WO2024220796A1 (fr) 2023-04-21 2024-10-24 Calcilytix Therapeutics, Inc. Traitement de l'hypoparathyroïdie à l'aide de composés triphényle calcilytiques

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE633760A (fr) * 1963-06-18
DD207203A1 (de) * 1982-06-21 1984-02-22 Peter Meisel Verfahren zur herstellung von epoxypropylethern
DE3743265A1 (de) * 1987-12-19 1989-06-29 Boehringer Ingelheim Kg Neue ammoniumverbindungen, ihre herstellung und verwendung
US5276008A (en) * 1990-08-09 1994-01-04 Bayer Aktiengesellschaft Substituted 4,5-diamino-1,2,4-triazol-3-(thi)ones
KR100251995B1 (ko) * 1991-08-23 2000-06-01 젠센 제임스 유. 칼슘 수용체 활성 분자
US6818660B2 (en) 1996-04-09 2004-11-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
BR9708632A (pt) 1996-04-09 2000-01-18 Nps Pharma Inc Composto calcilìticos
ES2171839T3 (es) * 1996-09-05 2002-09-16 Lilly Co Eli Analogos de carbazol como agonistas adrenergicos selectivos de beta3.
UY24949A1 (es) 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos
AR018177A1 (es) 1998-04-08 2001-10-31 Smithkline Beecham Corp Compuestos calciliticos, una composicion farmaceutica que los comprende y el uso de los mismos para la manufactura de un medicamento.
AR014975A1 (es) 1998-04-08 2001-04-11 Nps Pharma Inc Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento
US20020052509A1 (en) 1998-04-08 2002-05-02 Smithkline Beecham Corporation Calcilytic compounds and method of use
US6334338B1 (en) 1998-07-02 2002-01-01 Lucent Technologies Inc. Sol gel process of making a fiber preform with removal of oxide particles
US6291459B1 (en) 1998-08-12 2001-09-18 Smithkline Beecham Corporation Calcilytic compounds
US6335338B1 (en) 1998-08-12 2002-01-01 Smithkline Beecham Corporation Calcilytic compounds
NZ510760A (en) * 1998-10-23 2003-08-29 F Bicyclic nitrogen heterocycles
PE20001456A1 (es) 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
CA2382119A1 (fr) * 1999-08-27 2001-03-08 The Procter & Gamble Company Composants de formulation a action rapide, compositions et procedes de nettoyage utilisant ces composants
IL152925A (en) 1999-10-21 2010-04-15 Pfizer Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
US20030018203A1 (en) 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
MY159417A (en) 2000-01-24 2017-01-13 Smithkline Beecham Corp Calcilytic compounds
US6867299B2 (en) * 2000-02-24 2005-03-15 Hoffmann-La Roche Inc. Oxamide IMPDH inhibitors
CN1582275A (zh) 2000-07-21 2005-02-16 史密丝克莱恩比彻姆公司 钙拮抗化合物
US6916956B2 (en) 2000-08-11 2005-07-12 Japan Tobacco, Inc. Calcium receptor antagonist
AU2002230579A1 (en) 2000-10-25 2002-05-06 Smithkline Beecham Corp Calcilytic compounds
AU2002239489A1 (en) 2000-10-25 2002-05-21 Smithkline Beecham Corporation Calcilytic compounds
AR038658A1 (es) 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
US6864267B2 (en) 2001-07-16 2005-03-08 Smithkline Beecham Corporation Calcilytic compounds
JPWO2004106280A1 (ja) * 2003-05-28 2006-07-20 日本たばこ産業株式会社 CaSRアンタゴニスト

Also Published As

Publication number Publication date
EP1619180A1 (fr) 2006-01-25
ATE452121T1 (de) 2010-01-15
ES2337576T3 (es) 2010-04-27
US20080255042A1 (en) 2008-10-16
AR044075A1 (es) 2005-08-24
PT1619180E (pt) 2009-12-29
IL169575A0 (en) 2007-07-04
RU2315036C2 (ru) 2008-01-20
AU2004232604C1 (en) 2008-06-05
AU2004232604A1 (en) 2004-11-04
NO20054868D0 (no) 2005-10-21
CN101723921A (zh) 2010-06-09
JP3751312B2 (ja) 2006-03-01
US20120301552A1 (en) 2012-11-29
IL169575A (en) 2011-07-31
PE20050460A1 (es) 2005-07-08
HRP20100042T1 (hr) 2010-02-28
AU2004232604B2 (en) 2007-09-13
CO5640091A2 (es) 2006-05-31
PL1619180T3 (pl) 2010-05-31
MY138734A (en) 2009-07-31
DE602004024668D1 (de) 2010-01-28
MXPA05007609A (es) 2005-09-30
KR100696927B1 (ko) 2007-03-20
ZA200505587B (en) 2006-09-27
EP2189439A3 (fr) 2011-05-04
JPWO2004094362A1 (ja) 2006-07-13
EP2308828A3 (fr) 2013-05-22
SI1619180T1 (sl) 2010-04-30
TWI329628B (en) 2010-09-01
CN100577633C (zh) 2010-01-06
EP1619180A4 (fr) 2006-05-24
CN1741984A (zh) 2006-03-01
EP1619180B1 (fr) 2009-12-16
TW200505823A (en) 2005-02-16
US7304174B2 (en) 2007-12-04
CY1109880T1 (el) 2014-09-10
NZ541188A (en) 2008-01-31
EP2189439A2 (fr) 2010-05-26
HK1083096A1 (en) 2006-06-23
WO2004094362A1 (fr) 2004-11-04
CA2513738C (fr) 2010-04-06
EP2308828A2 (fr) 2011-04-13
AU2004232604B8 (en) 2004-11-04
AU2004232604A8 (en) 2004-11-04
CL2004000868A1 (es) 2005-01-21
BRPI0407097A (pt) 2006-01-24
RU2005123985A (ru) 2006-01-27
US20050032796A1 (en) 2005-02-10
KR20050094047A (ko) 2005-09-26
DK1619180T3 (da) 2010-03-29
CA2513738A1 (fr) 2004-11-04
US20090326058A1 (en) 2009-12-31

Similar Documents

Publication Publication Date Title
NO20054868L (no) CaSr antagonist
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
EP1630157A4 (fr) Antagoniste de casr
SE0302760D0 (sv) New compounds
NO20042811L (no) Substituerte henzoksazoler og analoger som estrogene midler
ECSP034744A (es) Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos
ZA200700765B (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
WO2006098918A3 (fr) Gamma lactames substitues en tant qu'agents therapeutiques
NO20062689L (no) Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer
NO20040881L (no) Orale antidiabetes midler.
CO5580767A2 (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
NO20062061L (no) Nye substituerte, 4-amino-tiazolo[4,5-D]pyriminder, nyttige som kjemokinreseptorantagonister, ESP. CX3CR1
DE60302157D1 (de) Opioidrezeptorantagonisten
NO20064078L (no) Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter
DK1511489T3 (da) Nye farmaceutiske sammensætninger indeholdende flibanserin-polymorf A
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
DK1814848T3 (da) 2,3,4-substitueret-cyclopentanoner som terapeutiske midler
NO20080669L (no) Acetylenpiperaziner som metabotrofiske glutamatreseptorantagonister
ATE389405T1 (de) Fexofenadine hydrochlorid polymorph
NO20044091L (no) Anvendelse av substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on for fremstilling av medikamenter som inhiberer pankreatisk lipase
ECSP034708A (es) Nueva sal de benzoilguanidina
ATE304012T1 (de) Vitronektin rezeptor antagonisten
BRPI0513549A (pt) composições farmacêuticas para o tratamento de leishmaniose
NO20056169L (no) 2,4-bis (trifluoroetoksy)pyridin-forbindelse og medikament inneholdende samme
WO2007023281A3 (fr) Composes biologiquement actifs

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application